Fresh clinical trial results released Saturday by high-flying biopharma Amarin have confirmed the heart-protecting benefits of Vascepa, its prescription drug derived from fish oil, suggesting it could become a blockbuster therapy, potentially prescribed to millions of Americans.

The company said in September that its treatment significantly reduced the risk of cardiovascular events compared with a placebo. Detailed results from the trial, known as REDUCE-IT, showed Vascepa cut the risk of death, heart attack, and stroke — the three most important cardiovascular events — by 26 percent.